Sanofi-aventis Canada announces licensing agreement with Intelliject for novel epinephrine auto injector
"This agreement is in line with sanofi-aventis' diversification strategy. It is also a clear example of actions sanofi-aventis
Under the terms of the agreement, sanofi-aventis will make an upfront payment and Intelliject will be eligible for future milestone payments and royalties on product sales.
According to Health
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Backed by a world-class R&D organization, the company is developing leading positions in several therapeutic areas: cardiology, thrombosis, oncology, metabolic disorders, the central nervous system, internal medicine and vaccines.
Sanofi-aventis is represented in
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended
--------------------------- (1) http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/allerg-eng.php, accessed Nov 2009 (2) www.allergysafecommunities.ca, accessed Nov 2009For further information: Christian Marcoux, Sanofi-aventis, (514) 956-4275; Stephanie Lyttle, NATIONAL Public Relations, (514) 842-2365